<DOC>
	<DOCNO>NCT03080545</DOCNO>
	<brief_summary>Patients receive biologic therapy 5 % less body surface area receive Enstilar topical foam 16 week .</brief_summary>
	<brief_title>Enstilar Combination With Biologic Agents</brief_title>
	<detailed_description>A two-phase , single center , observational study 25 subject assess 4 week adjunctive therapy Enstilar® QD follow 12 week QD two consecutive day week patient ≤5 % BSA receive biologic therapy least 24 week</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<criteria>1 . Male female adult ≥ 18 year age . 2 . Diagnosis chronic plaquetype psoriasis . 3 . Able give write informed consent prior performance study related procedure . 4 . Treated biologic agent minimum 24 week baseline . 5 . Plaquetype psoriasis define screen baseline BSA ≤ 5 % . 6 . Females childbearing potential ( FCBP ) must negative pregnancy test Screening Baseline . FCBP engage activity conception possible must use one approve contraceptive option : hormonal contraception ; intrauterine device ( IUD ) ; tubal ligation ; partner 's vasectomy ; Male female condom diaphragm spermicide , cervical cap spermicide , contraceptive sponge spermicide . 7 . Subject must general good health ( except psoriasis ) judge Investigator , base medical history , physical examination . 1 . &gt; 5 % Body Surface Area 2 . Any condition , would place subject unacceptable risk he/she participate study . 3 . Pregnant breast feeding , consider become pregnant study . 4 . Use investigational drug within 4 week prior randomization , within 5 pharmacokinetic/pharmacodynamic half life , know ( whichever longer ) . 5 . Use oral systemic medication treatment psoriasis within 4 week ( include , limited , oral corticosteroid , methotrexate , acitretin , apremilast cyclosporine ) . 6 . Patient use topical therapy treat within 2 week Baseline Visit ( include , limited , topical corticosteroid , vitamin D analog , retinoids ) . 7 . Patient receive UVB phototherapy within 2 week Baseline . 8 . Patient receive PUVA phototherapy within 4 week Baseline . 9 . Patient known hypersensitivity excipients Enstilar® state label .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>